Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized (from mouse) |
Target | PD-L1 |
Clinical data | |
Drug class | Antineoplastic agent |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
PubChem SID | |
UNII |
Adebrelimab is a drug that is being evaluated for the treatment of solid tumors. Adebrelimab is recombinant humanized IgG4 monoclonal antibody with specificity for PD-L1. [1] [2]
In 2023, adebrelimab was approved for use in China for the treatment of small cell lung cancer. [3]
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized (from mouse) |
Target | PD-L1 |
Clinical data | |
Drug class | Antineoplastic agent |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
PubChem SID | |
UNII |
Adebrelimab is a drug that is being evaluated for the treatment of solid tumors. Adebrelimab is recombinant humanized IgG4 monoclonal antibody with specificity for PD-L1. [1] [2]
In 2023, adebrelimab was approved for use in China for the treatment of small cell lung cancer. [3]